title: Hypercalcemia as a side effect of potassium binding agents.
abstract: Hypercalcemia is a potential adverse effect of calcium-containing ion exchange resins, often used in the treatment and prevention of hyperkalemia in chronic kidney disease (CKD). We describe a series of seven outpatients with moderate CKD (mean glomerular filtration rate estimated with the CKD-EPI formula 41.29 ± 10.83 mL/min/1.73 m(2)), presenting mild hypercalcemia in relation to the treatment with calcium polystyrene sulfonate. Serum calcium increased a mean of 0.91 ± 0.46 mg/dL, with a mean concomitant decrease of serum intact parathormone (iPTH) of 52.24 ± 49.29 ng/dL. After treatment withdrawal or dose reduction, we observed a recovery of serum calcium and iPTH values. Treatment with calcic potassium binders should be included in the differential diagnosis of hypercalcemia in patients with moderate CKD.
authors.affiliation: Servicio de Nefrología, Hospital Universitari Doctor Josep Trueta, Girona, Spain. dvdrry@gmail.com
authors.forename: David
authors.initials: D
authors.lastname: Arroyo
authors.forename: Nayara
authors.initials: N
authors.lastname: Panizo
authors.forename: Soledad
authors.initials: S
authors.lastname: García de Vinuesa
authors.forename: Marian
authors.initials: M
authors.lastname: Goicoechea
authors.forename: Ursula
authors.initials: U
authors.lastname: Verdalles
authors.forename: José
authors.initials: J
authors.lastname: Luño
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002614:Chelating Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D011137:Polystyrenes / Q000009:adverse effects*; D011188:Potassium
chemical_list: D002614:Chelating Agents; D011137:Polystyrenes; C003321:polystyrene sulfonic acid; D011188:Potassium